Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
AZTA 
Azenta Inc (AZTA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: AZTA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $33
1 Year Target Price $33
| 1 | Strong Buy |
| 1 | Buy |
| 5 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -17.33% | Avg. Invested days 40 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.37B USD | Price to earnings Ratio - | 1Y Target Price 33 |
Price to earnings Ratio - | 1Y Target Price 33 | ||
Volume (30-day avg) 7 | Beta 1.65 | 52 Weeks Range 23.91 - 55.63 | Updated Date 09/16/2025 |
52 Weeks Range 23.91 - 55.63 | Updated Date 09/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.28 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -16.68% | Operating Margin (TTM) 0.03% |
Management Effectiveness
Return on Assets (TTM) -1.6% | Return on Equity (TTM) -9.15% |
Valuation
Trailing PE - | Forward PE 29.07 | Enterprise Value 1093377332 | Price to Sales(TTM) 2.05 |
Enterprise Value 1093377332 | Price to Sales(TTM) 2.05 | ||
Enterprise Value to Revenue 1.63 | Enterprise Value to EBITDA 97.08 | Shares Outstanding 45839700 | Shares Floating 40458602 |
Shares Outstanding 45839700 | Shares Floating 40458602 | ||
Percent Insiders 1.8 | Percent Institutions 116.63 |
Upturn AI SWOT
Azenta Inc
Company Overview
History and Background
Azenta Inc., formerly Brooks Automation, was founded in 1978. Initially focused on robotics and automation for the semiconductor industry, it has evolved into a life sciences company providing sample management and genomics services. The company rebranded to Azenta in 2021 to reflect its focus on life sciences.
Core Business Areas
- Sample Management Solutions: Offers automated storage and handling solutions for biological samples, including cryogenic storage and tracking systems.
- Genomics Services: Provides genomic sequencing and synthesis services to support drug discovery and development.
- Multiomics Services: Offers an integrated approach combining genomics, proteomics, and metabolomics to provide comprehensive biological insights.
Leadership and Structure
Steve Schwartz serves as the President and CEO. The company is structured with distinct business units focused on sample management and genomics, supported by centralized corporate functions.
Top Products and Market Share
Key Offerings
- Automated Storage Systems: Provides automated storage solutions for biological samples, ranging from -20u00b0C to -196u00b0C. Competitors include Thermo Fisher Scientific, BioLife Solutions, and Hamilton Storage. Market share data unavailable publicly but is a significant player in this market. Revenue stream is part of Sample Management Solutions which generated revenue of 715.6 USD millions for FY 2023.
- Genomic Services (Sequencing & Synthesis): Offers a range of genomic services, including Sanger sequencing, next-generation sequencing (NGS), and custom gene synthesis. Competitors include Illumina, Thermo Fisher Scientific, and GenScript. Market share data unavailable publicly but is a significant player in this market. Revenue stream is part of the Genomics Services which generated revenue of 531.1 USD millions for FY 2023.
Market Dynamics
Industry Overview
The life sciences industry is experiencing significant growth, driven by advancements in genomics, personalized medicine, and drug discovery. Demand for sample management and genomic services is increasing.
Positioning
Azenta Inc. is positioned as a key provider of sample management and genomic solutions, serving pharmaceutical, biotech, and academic institutions. It differentiates itself through integrated solutions and a focus on high-quality data and service.
Total Addressable Market (TAM)
The TAM for sample management and genomics is estimated to be in the billions of dollars, growing rapidly. Azenta is well-positioned to capture a significant portion of this market due to its established presence and comprehensive product offerings.
Upturn SWOT Analysis
Strengths
- Strong market position in sample management solutions
- Comprehensive genomic services portfolio
- Established customer base in the life sciences industry
- Expertise in automation and cryogenic storage
Weaknesses
- Reliance on pharmaceutical and biotech R&D spending
- Competition from larger, diversified life sciences companies
- Potential for commoditization of genomic services
Opportunities
- Expansion into new geographic markets
- Development of novel genomic technologies
- Strategic acquisitions to expand product portfolio
- Increasing demand for personalized medicine solutions
Threats
- Economic downturns impacting R&D budgets
- Technological disruptions in genomic sequencing
- Increased regulatory scrutiny
- Emergence of new competitors
Competitors and Market Share
Key Competitors
- Thermo Fisher Scientific (TMO)
- Illumina (ILMN)
- Danaher Corporation (DHR)
Competitive Landscape
Azenta competes with larger, more diversified life sciences companies. Azenta focuses on niche markets like automated sample management and offers integrated solutions.
Major Acquisitions
B Medical Systems
- Year: 2022
- Acquisition Price (USD millions): 475
- Strategic Rationale: Expands Azenta's cold chain storage and transportation capabilities, complementing its existing sample management solutions.
Growth Trajectory and Initiatives
Historical Growth: Azenta Inc. has experienced significant growth through organic expansion and strategic acquisitions, particularly in the genomics services segment.
Future Projections: Analysts project continued revenue growth in the high single digits, driven by increased demand for sample management and genomic services. EPS is expected to grow at a faster pace due to operating leverage.
Recent Initiatives: Recent initiatives include the acquisition of B Medical Systems, expansion of genomic sequencing capabilities, and investments in automation technology.
Summary
Azenta Inc. demonstrates a robust presence in the life sciences sector, particularly in sample management and genomics services. The company's growth strategy, fueled by acquisitions and innovation, has led to increasing revenue and EPS. While competition from larger firms remains a challenge, Azenta's focus on niche markets and integrated solutions positions it well for future growth. Investors should monitor technological advancements and R&D spending trends within the biotech and pharmaceutical industries. The company should look to improve its market share in the competitive landscape.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (SEC)
- Investor Presentations
- Analyst Reports
- Company Website
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market data and analyst estimates are subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Azenta Inc
Exchange NASDAQ | Headquaters Burlington, MA, United States | ||
IPO Launch date 1995-02-02 | President, CEO & Director Mr. John P. Marotta | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 3000 | Website https://www.azenta.com |
Full time employees 3000 | Website https://www.azenta.com | ||
Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences market in the United States, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates through three reportable segments: Sample Management Solutions, Multiomics, and B Medical Systems. The Sample Management Solutions segment provides sample management products and solutions, including automated stores, cryogenic systems, automated sample tubes, consumables and instruments, and controlled rate thawing devices, as well as sample repository services. This segment also offers consultation services to clients throughout their experimental design and implementation processes. The Multiomics segment provides genomic and other sample analysis services comprising gene sequencing, synthesis editing, and related services. The B Medical Systems segment manufactures and distributes temperature-controlled storage and transportation solutions to governments, health institutions, and non-government organizations. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Burlington, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.